ArticleEJHaem2025
Early Epcoritamab Administration Revives CAR-T Cells in Relapsed/Refractory B-Cell Lymphomas.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL.Blood advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bispecific antibodies are effective for relapsed/refractory B-cell lymphoma patients even after CAR-T therapy. Methods: Peripheral blood CAR-T kinetics and functional analysis in vivo were carried out pre- and post-epcoritamab infusion in B-cell lymphoma patients relapsing after CAR-T therapy. Results: CAR copy numbers spiked at relapse and rose again following epcoritamab administration. Expression levels of CAR-T exhaustion markers did not increase, whereas perforin and granzyme B expression increased after epcoritamab induction. Conclusion: Early epcoritamab administration without cytotoxic agents at relapse after CAR-T therapy revives CAR-T cell numbers and cytotoxicity, which may potentially lead to favorable clinical outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.